The prices of Diphenhydramine Hydrochloride have tilted upward across the Asia-Pacific region in October 2025. The increase in market value was driven by a confluence of seasonal demand, active domestic buying and strategic pricing by the supplier. The end-user offtake for OTC antihistamine formulations in India was firm which was a result of seasonal shifts and downstream demand from consumer healthcare channels. The increased demand of Diphenhydramine Hydrochloride in the Indian domestic market of the antihistamine OTC formulations has encouraged the manufacturers to run strong production cycles. The suppliers have lifted the offers and leveraged firm offtake to protect their profit margins and support higher spot levels. The export market of Diphenhydramine Hydrochloride in China also moved in upward direction but marginally. The steady international and local procurement has maintained a gentle upward trajectory without triggering panic restocking. The inventory covers were adequate and buyers have adopted measured purchasing. The upstream production capability, downstream seasonal demand and supplier pricing strategy has pushed the spot prices higher across key APAC hubs.
